Boston Scientific to create 45 jobs in Galway

Boston Scientific Corporation (BSC) is to create 45 new high-calibre jobs in a research, development and innovation initiative, it was announced today.

The company, which specialises in medical devices for use in minimally invasive surgical procedures, is to invest a further €91m at its Galway site with the support of Government through IDA Ireland.

The investment will move BSC Galway’s R&D from late stage development to an earlier, innovative stage, requiring the development of new competencies and skill sets so that it can create new pioneering technology.

Tánaiste and Minister for Enterprise, Trade and Employment Mary Coughlan said: “Boston Scientific employs approximately 5,000 people in Ireland, 3,000 of which are located in Galway.

“This investment by BSC, a renowned global corporation and a reference life science company in Ireland, is an enormous boost of confidence in Ireland’s RD&I abilities.

“It elevates this country to an elite position among world locations which have the capability to support next generation research and innovation. The sheer scale, high complexity and critical strategic importance of this project to a global company of the calibre of BSC will further increase the focus of international foreign direct investors on Ireland, for both RD&I and for projects from all sectors.”

Hank Kucheman, Boston Scientific senior vice president and group president, cardiovascular, said: “We are pleased to make this strategic investment in Ireland, which builds on our positive and long established presence here and further demonstrates our commitment to the country.

“The performance and success of our Galway site, the high calibre of talented people in Ireland and the country’s commitment to RD&I, particularly through the innovative approaches of both the Government and IDA Ireland, gave us confidence that this was the correct setting for this important investment.

“We deeply appreciate the support of IDA for this project. Our activities in Ireland strengthen our company globally by ensuring the continued highest levels of innovation, manufacturing and value creation for patients, physicians, employees and shareholders.”